Select your country or region to view content specific to your country.
Jul 26, 2011
AnyplexTM Plus multiplex diagnostic test simultaneously identifies TB, multi-drug resistant TB and extensively multi-drug resistant TB
ROCKVILLE, Maryland and SEOUL, Korea, July xx, 2011 ? Seegene today announced Anyplex Plus, a total solution for diagnosing Tuberculosis (TB). Anyplex Plus is a nucleic acid amplification test (NAT) test that simultaneously detects a comprehensive range of TB - TB, MDR-TB, and XDR-TB - within three hours directly from a broad range of patient samples.
Every year 8 million people are newly infected with Tuberculosis (TB), and 2 million people die from the disease worldwide. TB infection rates show no signs of slowing, due in part to multi-drug resistant (MDR) and extensively drug-resistant (XDR) TB strains of the disease.
Successfully treating MDR-TB is extremely difficult, and the disease progresses faster than normal TB resulting in a 40-50% mortality rate. Therefore, it is critical to diagnose MDR-TB as quickly as possible and treat it before a patient can spread the disease further.
“Our main focus in developing Anyplex Plus was to diagnose not only TB and MDR-TB, but also XDR-TB. XDR-TB is resistant to Isoniazid and Rifampicin, any fluoroquinolone, and at least one of three injectable second-line drugs - amikacin, kanamycin, or capreomycin,” said Dr. Jong-Yoon Chun, Chief Executive Officer of Seegene.
Anyplex Plus screens for 5 mutations causing INH resistance, 15 mutations causing RIF resistance, 9 mutations causing FQ resistance, and 6 mutations causing injectable drug resistance.
Dr. Chun continued, “Making an accurate diagnosis quickly is crucial to curing a TB infection and limiting its spread to others. By providing a ‘one-stop’ test for TB, Anyplex Plus gives healthcare workers a power tool for rapid detection of a comprehensive range of TB. One that is at once effective, economical, and personalized.”
Seegene will showcase Anyplex Plus the 2011 Annual Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry in Atlanta, Ga., July 25-28, 2011.
AnyplexTM MDR-TB Test will not be available in the USA until regulatory clearance.
Seegene, Inc. is a leading molecular diagnostics company developing, manufacturing and marketing innovative “multiplex” (or “multi-pathogen detection”) molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex™ and Magicplex™ system which are Real-time PCR detection platform adapting DPO™ and READ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.comor call +301-762-9066.
Seegene Introduces Anyplex™ Plus Test, a total solution for diagnosing Tuberculosis AnyplexTM Plus multiplex diagnostic test simultaneously identifies TB, multi-drug resistant TB and extensively multi-drug resistant TB ROCKVILLE, Maryland and SEOUL, Korea, July ...